Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

被引：37

作者：

Mayence, Annie ^{[1
]}

Vanden Eynde, Jean Jacques ^{[2
]}

机构：

[1] Haute Ecole Prov Hainaut Condorcet, B-7330 St Ghislain, Belgium

[2] Univ Mons, Dept Organ Chem FS, B-7000 Mons, Belgium

来源：

PHARMACEUTICALS | 2019年 / 12卷 / 01期

关键词：

approved drugs; baricitinib; FDA; Janus kinases; protein kinase inhibitor; rheumatoid arthritis; DERIVATIVES BEARING; JAK INHIBITORS; IMMUNE; DISCOVERY; ARTHRITIS;

D O I：

10.3390/ph12010037

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.

引用

页数：7

共 29 条

[1]

[Anonymous], BAR

[2]

CenterWatch, FDA APPR DRUG

[3] Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases [J].

Clark, James D. ;

Flanagan, Mark E. ;

Telliez, Jean-Baptiste .

JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) :5023-5038

[4] 1H-pyrrolo[2,3-b]pyridine: A new scaffold for human neutrophil elastase (HNE) inhibitors [J].

Crocetti, Letizia ;

Giovannoni, Maria Paola ;

Schepetkin, Igor A. ;

Quinn, Mark T. ;

Khlebnikov, Andrei, I ;

Cantini, Niccolo ;

Guerrini, Gabriella ;

Iacovone, Antonella ;

Teodori, Elisabetta ;

Vergelli, Claudia .

BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (21) :5583-5595

[5]

Drugbank, TOF

[6] Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection [J].

Flanagan, Mark E. ;

Blumenkopf, Todd A. ;

Brissette, William H. ;

Brown, Matthew F. ;

Casavant, Jeffrey M. ;

Shang-Poa, Chang ;

Doty, Jonathan L. ;

Elliott, Eileen A. ;

Fisher, Michael B. ;

Hines, Michael ;

Kent, Craig ;

Kudlacz, Elizabeth M. ;

Lillie, Brett M. ;

Magnuson, Kelly S. ;

McCurdy, Sandra P. ;

Munchhof, Michael J. ;

Perry, Bret D. ;

Sawyer, Perry S. ;

Strelevitz, Timothy J. ;

Subramanyam, Chakrapani ;

Sun, Jianmin ;

Whipple, David A. ;

Changelian, Paul S. .

JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) :8468-8484

[7] Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 [J].

Fridman, Jordan S. ;

Scherle, Peggy A. ;

Collins, Robert ;

Burn, Timothy C. ;

Li, Yanlong ;

Li, Jun ;

Covington, Maryanne B. ;

Thomas, Beth ;

Collier, Paul ;

Favata, Margaret F. ;

Wen, Xiaoming ;

Shi, Jack ;

McGee, Ryan ;

Haley, Patrick J. ;

Shepard, Stacey ;

Rodgers, James D. ;

Yeleswaram, Swamy ;

Hollis, Greg ;

Newton, Robert C. ;

Metcalf, Brian ;

Friedman, Steven M. ;

Vaddi, Kris .

JOURNAL OF IMMUNOLOGY, 2010, 184 (09) :5298-5307

[8] The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders [J].

Furumoto, Yasuko ;

Gadina, Massimo .

BIODRUGS, 2013, 27 (05) :431-438

[9] Synthesis and structure-activity-relationship of 3,4-Diaryl-1H-pyrrolo[2,3-b]pyridines as irreversible Inhibitors of mutant EGFR-L858R/T790M [J].

Guenther, Marcel ;

Laux, Julian ;

Laufer, Stefan .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 128 :91-96

[10] Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor [J].

Hamaguchi, Hisao ;

Amano, Yasushi ;

Moritomo, Ayako ;

Shirakami, Shohei ;

Nakajima, Yutaka ;

Nakai, Kazuo ;

Nomura, Naoko ;

Ito, Misato ;

Higashi, Yasuyuki ;

Inoue, Takayuki .

BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (18) :4971-4983

← 1 2 3 →